AzTrials
AzTrials

Multiple System AtrophySTAG-MSANCT03593512

Deep Brain Stimulation for Autonomic and Gait Symptoms in Multiple System Atrophy

A study testing Deep brain stimulation in people with Multiple System Atrophy and Autonomic Failure, run by University of Oxford at 1 site in United Kingdom.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Patients referred to neurosurgery routinely and safely undergo deep brain stimulation (DBS) for treatment of symptoms related to neurodegenerative conditions, most commonly Parkinson's disease. In the investigators experience, and published evidence shows, that stimulation has effects on the autonomic nervous system. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Deep brain stimulation
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
5 participants
Where
1 siteUnited Kingdom
Study dates
9 Sep 2018to 8 Aug 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Diagnosis of MSA with disabling autonomic symptoms (bladder dysfunction and orthostatic symptoms
  • UMSARS score of >40
  • >6/12 in the autonomic subsection (Q9-12) of the UMSAR scale
  • Patient willing and able to give informed consent to involvement in the study.
  • Male or female, aged 18 years or over.
  • Able to walk unaided (to perform gait analysis)
  • Have an anticipated prognosis > 2 years

Who cannot join

  • The patient is unwilling to participate or unable to give informed consent.
  • The patient has been deemed unfit for stimulator insertion by their healthcare team i.e. surgical contraindications to DBS:
  • Bleeding or coagulation disorder
  • Not fit for general anaesthetic
  • Unable to deal with implanted DBS system (turn on and off and recharging where applicable, although it is acceptable if a carer can do this)
  • Untreated anxiety or depression
Show all 9Show fewer
  • Unable to undergo MRI (eg. metal implants)
  • Subject is currently participating in a clinical investigation that includes an active treatment arm.
  • Female who is pregnant - testing will be offered to female patients who are unsure.

Trial locations and contacts

1 site in 1 country.

United Kingdom1 site
  • John Radcliffe Hospital

    Oxford, Oxfordshire, OX3 9DU

Other trials in United Kingdom

About this study

Patients referred to neurosurgery routinely and safely undergo deep brain stimulation (DBS) for treatment of symptoms related to neurodegenerative conditions, most commonly Parkinson's disease.

In the investigators experience, and published evidence shows, that stimulation has effects on the autonomic nervous system. In patients undergoing therapeutic DBS for a particular subtype of Parkinsonism, Multiple System Atrophy, the further effects on autonomic parameters such as blood pressure and bladder symptoms as well as the originally intended indications (gait and movement disorder) will be investigated. The mechanisms of any effects will also be studied by using a number of techniques such as magnetoencephalography (MEG) and Muscle Sympathetic Nerve Activity (MSNA) recording.

Read more

Key goals are to:

  1. Demonstrate that stimulation of the peduculopontine nucleus (PPN) improves autonomic function and has an attendant improvement on patients' quality of life
  2. Investigate the role of the PPN and how it interacts with other brain areas.

This translational strategy will lead to a larger efficacy study of DBS for MSA as well as revolutionizing neural-based treatments in other autonomic disorders such as orthostatic hypotension and pure autonomic failure.

Read the detailed description

AIMS OF THE PROJECT AND IMPORTANCE

Multiple system atrophy (MSA) is a form of Parkinsonism and is a neurodegenerative condition that is characterized by gait and autonomic failure. MSA symptoms are generally poorly responsive to medicines that treat Parkinson's disease (PD), and so symptom control is difficult.

The aim is to assess the effects of deep brain stimulation (DBS) of the pedunculopontine nucleus (PPN) on autonomic and gait symptoms to show that it improves quality of life in patients with MSA.

Secondary aims are to assess the effects of stimulation on autonomic parameters (cardiovascular and bladder function) as well as the routine parameters of the movement disorder (gait, freezing and falls, etc).

In addition, there is a mechanistic component of the study looking at both peripheral autonomic activity and brain networks associated with stimulation.

BACKGROUND AND WORK LEADING UP TO THE PROJECT

DBS is a routine treatment for movement disorders such as Parkinson's disease and dystonia. MSA is a 'Parkinsonian' condition similar to PD and is a progressive, incurable, neurodegenerative condition characterized by a combination of Parkinsonism, ataxia, and autonomic failure. Autonomic dysfunction is the presenting feature in half of patients that have Parkinsonism or ataxia predominant MSA.

Whilst DBS is sometimes performed for the treatment of MSA, the primary outcome measure is usually the motor outcome, despite the fact that the autonomic symptoms may be the predominant factor in causing a reduced quality of life. This is because DBS is traditionally used to control motor symptoms and the exploration of its effects on autonomic function are relatively new, and pioneered by our group. The most common complaints caused by autonomic dysfunction in MSA are related to orthostatic hypotension and neurogenic bladder, both of which have been studied by the investigators previously.

Part of the aim of this study is to look at orthostatic BP changes with and without stimulation and see whether these are improved by DBS. Bladder dysfunction includes incontinence and incomplete emptying. These will be investigated using urodynamic testing, with a standard protocol. Other 'autonomic' problems include sleep disorders, exercise intolerance and problems with thermoregulation and sweating. These will be captured using questionnaires.

Regarding the target used for DBS, a well-established target to improve gait and postural abnormalities in PD is the pedunculopontine nucleus (PPN). The investigators have previously demonstrated that the PPN is also a brain area that, when stimulated, improves bladder function in these patients. They have also shown (unpublished data) that PPN stimulation reduces postural fall in BP in a group of PD patients treated primarily for gait and postural problems. It has also been shown that stimulation of a related brain area can improve orthostatic hypotension.

Mechanistic Studies

These are important in order to understand how PPN DBS alters autonomic function. Previously, the investigators have studied the effects of central stimulation of the subthalamic nucleus and periaqueductal grey area (amongst others) on peripheral sympathetic nerve activity. These techniques (muscle sympathetic nerve activity (MSNA)) will be applied in the current study to find out whether PPN DBS alters peripheral sympathetic nervous system activity.

To look at central mechanisms, two techniques will be used. Firstly, diffusion tensor imaging is routinely obtained as part of surgical planning. The hypothesis is that connections from PPN to areas that are part of the central autonomic network are important for influencing autonomic control. By looking at tracts to and from the target area, it will be investigated whether connections to the rostroventrolateral medulla (RVLM) are important for changes in MSNA. The RVLM is an important area that receives feedback from the periphery and is in turn influenced by higher centres.

A second part of the central mechanism study will utilize MEG scanning. The investigators have previously applied this technique to patients who have undergone DBS. The investigator are interested in whether PPN DBS alters cortical activity, both in the insula and anterior cingulate cortices (these are important in autonomic control) and also the motor cortex (important for motor control).

KEY METHODOLOGIES AND TECHNIQUES

Recruitment

Patients will be identified in a movement disorder clinic by a consultant neurologist. If they decide to take part, they will attend to proceed with the consent process and baseline measurements. The pathway for each participant through the study will follow a standardized pattern that is essentially identical to the pathway that current DBS patients for all movement disorder indications go through.

Baseline Assessments

  1. Questionnaires
  2. EQ-5D - quality of life questionnaire
  3. UMSARS - Unified MSA rating scale
  4. Freezing of Gait (FOG) Questionnaire
  5. Autonomic questionnaire
  6. Falls diary
  7. Neuropsychology assessment. Includes HAD, FLP and MOCA questionnaires and interview.
  8. MRI scan with DTI. This is routine for surgical planning.
  9. Gait analysis. Patients will be asked to walk along a special gait flooring which will allow us to obtain specific parameters concerning their gait.
  10. Urodynamics and Cardiovascular tests
  11. Urodynamics The 'gold standard' is video urodynamics. This involves urethral catheterisation and insertion of a rectal probe and measurements of detrusor pressures, bladder capacity, reflux, sensory urgency and voiding differences such as rate of urinary flow. Patients who are unwilling to undergo these tests will still fill in voiding diaries and urinary symptom questionnaires that are part of the questionnaires listed above.
  12. Tilt table tests Patients will undergo continuous ECG monitoring whilst standing upright and then whilst tilted into a lying down position using the tilt table. Changes in heart rate, heart rate variability and blood pressure will be recorded and integrated using our analysis program.
  13. Ambulatory BP

This involves wearing a blood pressure cuff for 24 hours, which will be timed with the other baseline assessments or, if the participant prefers, this can be done at home.

Subsequent Visits

  1. Surgery This will follow routine clinical practice. Electrodes will be implanted under general anaesthetic using a standard stereotactic frame. Electrodes will be externalized for a week of clinical testing. During the week of testing, the priority will be to titrate the stimulator for clinical effects. Further gait analysis, tilt table tests and ambulatory BP may be used to inform parameter settings. In addition, we may perform local field potential recordings (recording electrical activity from the electrodes) during these tests. This will give information as to how the PPN is responding to movement and tilt etc. At the end of one week, a second procedure will be performed to insert the implantable pulse generator (the battery). They will return at 6 weeks for stimulator titration only (this is part of routine care).
  2. 3 month primary outcome follow up
  3. Questionnaires (section 1 and 2 in baseline assessments above) will be performed as at baseline except the full neuropsychology assessment will not be performed (just the HADS, FLP and MOCA).
  4. The following tests will be repeated on and off stimulation; i) Urodynamics ii) Tilt table tests iii) Gait analysis
  5. The participants will attend for a second day and will undergo two further tests ON and OFF stimulation
  6. Magnetoencephalography (MEG) scan. This records cortical signals ON and OFF stimulation with the aim of demonstrating how PPN suppression or excitation alters cortical activity, especially in the areas important for autonomic and motor control ii. MSNA (microneurography). This technique entails insertion of two very fine needles (30-40microns in diameter) below the knee. The first will record directly from the common peroneal nerve whilst the second will lie subcutaneously as a reference. This is an established technique for measuring peripheral sympathetic activity. Neurograms will be recorded with stimulation ON and then OFF during the same sitting. The aim is to establish whether any changes in autonomic symptomatology are correlated with changes in sympathetic nerve activity, thereby providing a mechanism of action. iii. Sleep EEG studies with varying stimulation ON and OFF in order to investigate the role of the PPN in sleep stages and EEG waveforms.
Being tested
Deep brain stimulation
Keywords
multiple system atrophy, autonomic
Medical subject headings
Multiple System Atrophy, Pure Autonomic Failure, Hypotension, Orthostatic, Urinary Bladder, Neurogenic, Gait Disorders, Neurologic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Deep brain stimulationProcedure or surgery

    Bilateral deep brain stimulation of the pedunculopontine nucleus

Study groups in NCT03593512
Study groupRoleWhat they receive
PPN DBSExperimentalAll patients will undergo bilateral PPN DBS
Receives: Procedure: Deep brain stimulation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. EuroQol 5 Dimension (5 level) score before and after deep brain stimulation

    Measurement of quality of life before and after surgery. Results will be given as description of health states - it is not quantitative.

    Measured: Through study completion, but on average, over an 8 month period for each patient

  2. Fluency of gait as measured by accelerometry before and after deep brain stimulation

    Measurement of gait parameters before and after surgery

    Measured: Through study completion, but on average, over an 8 month period for each patient

  3. Modified composite autonomic symptom scale before and after deep brains stimulation

    Measurement of autonomic symptomatology before and after surgery - Score from 0-100

    Measured: Through study completion, but on average, over an 8 month period for each patient

  4. Change in postural blood pressure change before and after PPN DBS

    Measurement of effect on postural blood pressure change before and after surgery

    Measured: Through study completion, but on average, over an 8 month period for each patient

Secondary outcomes (4)
  1. Number of Participants With Treatment-Related Adverse Events as Assessed by using approved UK reporting procedure

    To assess the safety of PPN DBS on MSA patients by recording adverse events

    Measured: Through study completion, 2 years

  2. Muscle sympathetic nerve activity before and after deep brain stimulation

    To determine whether or not PPN suppression or excitation alters sympathetic outflow by measuring the activity in autonomic nerves in the leg

    Measured: Through study completion, but on average, over an 8 month period for each patient

  3. Cortical magentoencephalography profile with deep brain stimulation on and off

    Identification in change of cortical magetic activity with DBS on and off

    Measured: 3-6 months after surgery

  4. Physical anatomical white matter connections between the pedunculopontine nucleus and the rest of the central nervous system

    To identify the physical anatomical relations of the stimulated region of brain by looking at high resolution structural imaging studies

    Measured: Before surgery and 3-6 months after surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Jul 2018
  2. Study start9 Sep 2018
  3. Primary completion1 Dec 2021
  4. Study completion8 Aug 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
Evaluation of symptomatology before and after implantation of DBS electrodes; followed by cross-over of "on" and "off" stimulation
Masking
None (open label)
Enrolment
5 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03593512
Sponsor's protocol ID
13340
Acronym
STAG-MSA
Status last verified
May 2022
First submitted
22 May 2018
Last updated
2 Nov 2022
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: We are recruiting only 10 patients, so sharing IPD even anonymised, may be identifiable. Decision will be taken when this can be definitively elucidated.

Questions about this trial

What is this clinical trial studying?

A study testing Deep brain stimulation in people with Multiple System Atrophy and Autonomic Failure, run by University of Oxford at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 2 Nov 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

EuroQol 5 Dimension (5 level) score before and after deep brain stimulation (time frame: Through study completion, but on average, over an 8 month period for each patient). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Nov 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in